Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced highlights of PRP, its lead proenzyme therapy poised to potentially disrupt the $3 billion+ pancreatic cancer treatment market—one of oncology's most desperate battlegrounds with a grim 13% five-year survival rate.

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game:

- >85% tumor growth inhibition demonstrated in preclinical pancreatic models  

- Forces malignant cells to differentiate—attacking cancer at its root  

- Reduces fibrosis and resistance markers in the tumor microenvironment  

- Sensitizes resistant tumors to standard chemo—higher efficacy, lower toxicity  

- Targets cancer stem cells to cut recurrence risk

Propanc is advancing PRP toward clinical development for advanced solid tumors, with pancreatic and ovarian cancers as initial priorities.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.